metoprolol has been researched along with Disease Exacerbation in 29 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to test the hypothesis that the beta-blocker metoprolol succinate controlled release/extended release (CR/XL), when given to patients with hypercholesterolemia on concomitant lipid-lowering therapy, provides an additional antiatherosclerotic effect to that provided by the statins, measured as carotid intima-media thickness (IMT)." | 9.10 | Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. ( Bondjers, G; Hulthe, J; Olofsson, SO; Schmidt, C; Wiklund, O; Wikstrand, J, 2002) |
| "Metoprolol CR/XL effectively decreases mortality and improves clinical status in patients with stable mild to moderate (NYHA functional class II or III) chronic heart failure due to left ventricular systolic dysfunction, and the drug is effective in patients with ischaemic or dilated cardiomyopathy." | 8.80 | Metoprolol: a review of its use in chronic heart failure. ( Markham, A; Prakash, A, 2000) |
| "Acute intravenous infusion of ranolazine (Ran), an anti-ischemic/antiangina drug, was previously shown to improve left ventricular (LV) ejection fraction (EF) without a concomitant increase in myocardial oxygen consumption in dogs with chronic heart failure (HF)." | 7.74 | Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. ( Belardinelli, L; Blackburn, B; Gupta, RC; Mishra, S; Rastogi, S; Sabbah, HN; Sharov, VG; Stanley, WC, 2008) |
| "Metabolic, hemodynamic, and electrophysiological parameters were studied in all the patients on hospital stay days I and S." | 5.36 | [Efficacy of ivabradine in combination therapy for complicated acute coronary syndrome in patients with type 2 diabetes mellitus]. ( Dolgikh, VT; Kondrat'ev, AI; Stotskiĭ, AO, 2010) |
| " The aim of this study was to test the hypothesis that the beta-blocker metoprolol succinate controlled release/extended release (CR/XL), when given to patients with hypercholesterolemia on concomitant lipid-lowering therapy, provides an additional antiatherosclerotic effect to that provided by the statins, measured as carotid intima-media thickness (IMT)." | 5.10 | Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. ( Bondjers, G; Hulthe, J; Olofsson, SO; Schmidt, C; Wiklund, O; Wikstrand, J, 2002) |
| "Metoprolol CR/XL effectively decreases mortality and improves clinical status in patients with stable mild to moderate (NYHA functional class II or III) chronic heart failure due to left ventricular systolic dysfunction, and the drug is effective in patients with ischaemic or dilated cardiomyopathy." | 4.80 | Metoprolol: a review of its use in chronic heart failure. ( Markham, A; Prakash, A, 2000) |
| "We used a New Zealand white rabbit model of cationized bovine serum albumin (cBSA)-induced glomerulonephritis and then administered them metoprolol, irbesartan or acupuncture to evaluate the effectiveness of acupuncture treatment and preliminarily explore its potential mechanism." | 3.80 | "Qufeng Tongluo" acupuncture prevents the progression of glomerulonephritis by decreasing renal sympathetic nerve activity. ( An, P; Dang, HM; Shi, XM; Wu, XL; Ye, BY, 2014) |
| "Acute intravenous infusion of ranolazine (Ran), an anti-ischemic/antiangina drug, was previously shown to improve left ventricular (LV) ejection fraction (EF) without a concomitant increase in myocardial oxygen consumption in dogs with chronic heart failure (HF)." | 3.74 | Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. ( Belardinelli, L; Blackburn, B; Gupta, RC; Mishra, S; Rastogi, S; Sabbah, HN; Sharov, VG; Stanley, WC, 2008) |
| "Pulmonary hypertension (PH) in COPD confers increased risk of exacerbations (ECOPD)." | 3.30 | Association between P-pulmonale and respiratory morbidity in COPD: a secondary analysis of the BLOCK-COPD trial. ( Bittner, V; Dransfield, MT; Helgeson, ES; Kunisaki, KM; Lammi, MR; Ling, SX; MacDonald, DM; Mkorombindo, T; Pew, K; Voelker, H; Wade, RC, 2023) |
| "Among patients with moderate or severe COPD who did not have an established indication for beta-blocker use, the time until the first COPD exacerbation was similar in the metoprolol group and the placebo group." | 2.90 | Metoprolol for the Prevention of Acute Exacerbations of COPD. ( Bhatt, SP; Brenner, K; Casaburi, R; Come, CE; Connett, JE; Cooper, JAD; Criner, GJ; Curtis, JL; Dransfield, MT; Han, MK; Hatipoğlu, U; Helgeson, ES; Jain, VV; Kalhan, R; Kaminsky, D; Kaner, R; Kunisaki, KM; Lambert, AA; Lammi, MR; Lazarus, SC; Lindberg, S; Make, BJ; Martinez, FJ; McEvoy, C; Panos, RJ; Reed, RM; Scanlon, PD; Sciurba, FC; Smith, A; Sriram, PS; Stringer, WW; Voelker, H; Weingarten, JA; Wells, JM; Westfall, E, 2019) |
| "A substantial majority of chronic obstructive pulmonary disease (COPD)-related morbidity, mortality and healthcare costs are due to acute exacerbations, but existing medications have only a modest effect on reducing their frequency, even when used in combination." | 2.82 | β-Blockers for the prevention of acute exacerbations of chronic obstructive pulmonary disease (βLOCK COPD): a randomised controlled study protocol. ( Bhatt, SP; Connett, JE; Criner, GJ; Dransfield, MT; Lazarus, SC; Lindberg, SM; Voelker, H; Wells, JM; Westfall, E, 2016) |
| "The magnitude of proteinuria is associated with a graded increase in the risk of progression to end-stage renal disease and cardiovascular events." | 2.71 | The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. ( Bakris, GL; Greene, T; Hebert, L; Lea, J; Lipkowitz, M; Massry, S; Middleton, J; Miller, E; Rostand, SG; Smith, W, 2005) |
| "Fatigue, but not breathlessness, remained a significant predictor for developing worsening heart failure (RR 1." | 2.71 | Symptoms in patients with heart failure are prognostic predictors: insights from COMET. ( Charlesworth, A; Cleland, JG; Ekman, I; Metra, M; Poole-Wilson, PA; Swedberg, K, 2005) |
| "Hypertension is a leading cause of end-stage renal disease (ESRD) in the United States, with no known treatment to prevent progressive declines leading to ESRD." | 2.70 | Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. ( Agodoa, LY; Appel, LJ; Bakris, G; Charleston, J; Cheek, D; Douglas-Baltimore, JG; Gassman, J; Glassock, R; Greene, T; Hebert, L; Jamerson, K; Lewis, J; Middleton, JP; Phillips, RA; Rostand, SG; Toto, RD; Wright, JT, 2002) |
| "Obesity is a significant risk factor for hypertension and the cardiovascular sequelae of hypertension." | 2.69 | The effect of weight loss intervention on antihypertensive medication requirements in the hypertension Optimal Treatment (HOT) study. ( Adair, CT; Anderson, DC; Cameron, ME; Jones, DW; King, NS; Miller, ME; Willoughby, DL; Wofford, MR, 1999) |
| " To date, controlled clinical trials performed in more than 13,000 patients with chronic heart failure have consistently shown that the long term administration of beta-blockers is associated with significant improvement in left ventricular function, clinical symptoms, and survival." | 2.41 | [Role of beta-blockers in the treatment of chronic heart heart failure]. ( Czuriga, I; Edes, I, 2001) |
| "Metoprolol treatment reduced overall mortality (10% vs 26%, p = 0." | 1.56 | Metoprolol blunts the time-dependent progression of infarct size. ( Fuster, V; Galán-Arriola, C; García-Ruiz, JM; González-Del-Hoyo, M; Higuero-Verdejo, MI; Ibanez, B; Lobo-Gonzalez, M; López-Martín, GJ; Oliver, E; Pizarro, G; Rossello, X; Sánchez-González, J; Vilchez, JP, 2020) |
| "Within the COPD GOLD II stage group, there appears to be no statistically significant difference in the number of exacerbations between the patients taking verapamil and digoxin (n = 24) and the patients taking BBs alone (n = 15), although, in patients taking BBs alone, there appears to be a trend towards a decrease in the exacerbations compared to the number of exacerbations in patients taking verapamil and digoxin (p = 0." | 1.51 | Beta-blocker Use in Moderate and Severe Chronic Obstructive Pulmonary Disease. ( Bedak, O; Begic, E; Bradaric, H; Custovic, F; Durak-Nalbantic, A; Hodzic, E; Mujakovic, A; Prnjavorac, B; Zvizdic, F, 2019) |
| "Bisoprolol was found to reduce mortality and CHF exacerbation compared to carvedilol and metoprolol." | 1.46 | The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study. ( Chen, CY; Huang, YB; Kuo, CC; Liao, KM; Lin, TY, 2017) |
| "Metabolic, hemodynamic, and electrophysiological parameters were studied in all the patients on hospital stay days I and S." | 1.36 | [Efficacy of ivabradine in combination therapy for complicated acute coronary syndrome in patients with type 2 diabetes mellitus]. ( Dolgikh, VT; Kondrat'ev, AI; Stotskiĭ, AO, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.45) | 18.2507 |
| 2000's | 12 (41.38) | 29.6817 |
| 2010's | 13 (44.83) | 24.3611 |
| 2020's | 3 (10.34) | 2.80 |
| Authors | Studies |
|---|---|
| Wade, RC | 1 |
| Mkorombindo, T | 1 |
| Ling, SX | 1 |
| Helgeson, ES | 2 |
| MacDonald, DM | 1 |
| Pew, K | 1 |
| Voelker, H | 3 |
| Bittner, V | 1 |
| Kunisaki, KM | 2 |
| Lammi, MR | 2 |
| Dransfield, MT | 3 |
| Zvizdic, F | 1 |
| Begic, E | 1 |
| Mujakovic, A | 1 |
| Hodzic, E | 1 |
| Prnjavorac, B | 1 |
| Bedak, O | 1 |
| Custovic, F | 1 |
| Bradaric, H | 1 |
| Durak-Nalbantic, A | 1 |
| Bhatt, SP | 2 |
| Brenner, K | 1 |
| Casaburi, R | 1 |
| Come, CE | 1 |
| Cooper, JAD | 1 |
| Criner, GJ | 2 |
| Curtis, JL | 1 |
| Han, MK | 1 |
| Hatipoğlu, U | 1 |
| Jain, VV | 1 |
| Kalhan, R | 1 |
| Kaminsky, D | 1 |
| Kaner, R | 1 |
| Lambert, AA | 1 |
| Lindberg, S | 1 |
| Make, BJ | 1 |
| Martinez, FJ | 1 |
| McEvoy, C | 1 |
| Panos, RJ | 1 |
| Reed, RM | 1 |
| Scanlon, PD | 1 |
| Sciurba, FC | 1 |
| Smith, A | 1 |
| Sriram, PS | 1 |
| Stringer, WW | 1 |
| Weingarten, JA | 1 |
| Wells, JM | 2 |
| Westfall, E | 2 |
| Lazarus, SC | 2 |
| Connett, JE | 2 |
| Lobo-Gonzalez, M | 1 |
| Galán-Arriola, C | 1 |
| Rossello, X | 1 |
| González-Del-Hoyo, M | 1 |
| Vilchez, JP | 1 |
| Higuero-Verdejo, MI | 1 |
| García-Ruiz, JM | 1 |
| López-Martín, GJ | 1 |
| Sánchez-González, J | 1 |
| Oliver, E | 1 |
| Pizarro, G | 1 |
| Fuster, V | 1 |
| Ibanez, B | 1 |
| Posielski, NM | 1 |
| Richards, KA | 1 |
| Liou, JI | 1 |
| Borza, T | 1 |
| Abel, EJ | 1 |
| Downs, TM | 1 |
| Jarrard, DF | 1 |
| Liao, KM | 1 |
| Lin, TY | 1 |
| Huang, YB | 1 |
| Kuo, CC | 1 |
| Chen, CY | 1 |
| Khatir, DS | 1 |
| Pedersen, M | 1 |
| Ivarsen, P | 1 |
| Christensen, KL | 1 |
| Jespersen, B | 1 |
| Buus, NH | 1 |
| Fonarow, G | 1 |
| Castaldi, A | 1 |
| Zaglia, T | 1 |
| Di Mauro, V | 1 |
| Carullo, P | 1 |
| Viggiani, G | 1 |
| Borile, G | 1 |
| Di Stefano, B | 1 |
| Schiattarella, GG | 1 |
| Gualazzi, MG | 1 |
| Elia, L | 1 |
| Stirparo, GG | 1 |
| Colorito, ML | 1 |
| Pironti, G | 1 |
| Kunderfranco, P | 1 |
| Esposito, G | 1 |
| Bang, ML | 1 |
| Mongillo, M | 1 |
| Condorelli, G | 1 |
| Catalucci, D | 1 |
| An, P | 1 |
| Dang, HM | 1 |
| Shi, XM | 1 |
| Ye, BY | 1 |
| Wu, XL | 1 |
| Lindberg, SM | 1 |
| Sehnert, AJ | 1 |
| Daniels, SE | 1 |
| Elashoff, M | 1 |
| Wingrove, JA | 1 |
| Burrow, CR | 1 |
| Horne, B | 1 |
| Muhlestein, JB | 1 |
| Donahue, M | 1 |
| Liggett, SB | 1 |
| Anderson, JL | 1 |
| Kraus, WE | 1 |
| Rastogi, S | 1 |
| Sharov, VG | 1 |
| Mishra, S | 1 |
| Gupta, RC | 1 |
| Blackburn, B | 1 |
| Belardinelli, L | 1 |
| Stanley, WC | 1 |
| Sabbah, HN | 1 |
| Venkataraman, G | 1 |
| Strickberger, SA | 1 |
| Kondrat'ev, AI | 1 |
| Dolgikh, VT | 1 |
| Stotskiĭ, AO | 1 |
| Remme, WJ | 1 |
| Nicholson, DJ | 1 |
| Passen, EL | 1 |
| Wann, S | 1 |
| McMurray, JJ | 1 |
| Bolduc, V | 1 |
| Drouin, A | 1 |
| Gillis, MA | 1 |
| Duquette, N | 1 |
| Thorin-Trescases, N | 1 |
| Frayne-Robillard, I | 1 |
| Des Rosiers, C | 1 |
| Tardif, JC | 1 |
| Thorin, E | 1 |
| Wright, JT | 1 |
| Bakris, G | 1 |
| Greene, T | 2 |
| Agodoa, LY | 1 |
| Appel, LJ | 1 |
| Charleston, J | 1 |
| Cheek, D | 1 |
| Douglas-Baltimore, JG | 1 |
| Gassman, J | 1 |
| Glassock, R | 1 |
| Hebert, L | 2 |
| Jamerson, K | 1 |
| Lewis, J | 1 |
| Phillips, RA | 1 |
| Toto, RD | 1 |
| Middleton, JP | 1 |
| Rostand, SG | 2 |
| Abraham, WT | 1 |
| Gilbert, EM | 1 |
| Lowes, BD | 1 |
| Minobe, WA | 1 |
| Larrabee, P | 1 |
| Roden, RL | 1 |
| Dutcher, D | 1 |
| Sederberg, J | 1 |
| Lindenfeld, JA | 1 |
| Wolfel, EE | 1 |
| Shakar, SF | 1 |
| Ferguson, D | 1 |
| Volkman, K | 1 |
| Linseman, JV | 1 |
| Quaife, RA | 1 |
| Robertson, AD | 1 |
| Bristow, MR | 1 |
| Lea, J | 1 |
| Lipkowitz, M | 1 |
| Massry, S | 1 |
| Middleton, J | 1 |
| Miller, E | 1 |
| Smith, W | 1 |
| Bakris, GL | 1 |
| Ekman, I | 1 |
| Cleland, JG | 1 |
| Swedberg, K | 1 |
| Charlesworth, A | 1 |
| Metra, M | 1 |
| Poole-Wilson, PA | 1 |
| Yee, J | 1 |
| Jones, DW | 1 |
| Miller, ME | 1 |
| Wofford, MR | 1 |
| Anderson, DC | 1 |
| Cameron, ME | 1 |
| Willoughby, DL | 1 |
| Adair, CT | 1 |
| King, NS | 1 |
| Prakash, A | 1 |
| Markham, A | 1 |
| Czuriga, I | 1 |
| Edes, I | 1 |
| Tsuyuki, RT | 1 |
| McKelvie, RS | 1 |
| Arnold, JM | 1 |
| Barretto, AC | 1 |
| Carvalho, AC | 1 |
| Isaac, DL | 1 |
| Kitching, AD | 1 |
| Piegas, LS | 1 |
| Teo, KK | 1 |
| Yusuf, S | 1 |
| Wiklund, O | 1 |
| Hulthe, J | 1 |
| Wikstrand, J | 1 |
| Schmidt, C | 1 |
| Olofsson, SO | 1 |
| Bondjers, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Beta-Blockers for the Prevention of Acute Exacerbations of COPD[NCT02587351] | Phase 3 | 532 participants (Actual) | Interventional | 2016-05-01 | Terminated (stopped due to Futility) | ||
| Effect of Pharmacological Heart Rate Reduction on Visco-elastic Properties of the Arterial Wall (BRADYVASC)[NCT02584439] | Phase 3 | 30 participants (Anticipated) | Interventional | 2015-10-31 | Recruiting | ||
| African American Study of Kidney Disease and Hypertension[NCT04364139] | Phase 3 | 1,094 participants (Actual) | Interventional | 1995-02-01 | Completed | ||
| Effect of Renin-angiotensin-system (RAS) Blocker Drugs on Chronic Kidney Disease (CKD) Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01)[NCT03195023] | Phase 4 | 106 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| Multicentre Prospective Open Label Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.[NCT04662723] | Phase 4 | 878 participants (Anticipated) | Interventional | 2023-05-01 | Recruiting | ||
| Effects of a Mindfulness-Based Intervention on Symptoms and Signs, Well-Being and Health in Patients With Chronic Heart Failure[NCT04871178] | 50 participants (Actual) | Interventional | 2010-10-10 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
All-cause mortality count (NCT02587351)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Metoprolol Succinate | 11 |
| Placebo | 5 |
COPD Assessment Test (CAT) change from baseline. The CAT is a simple, eight item, health status instrument for patients with COPD that provides a score of 0-40. Lower scores denote better health status. (NCT02587351)
Timeframe: Baseline, 1 year
| Intervention | score on a scale (Mean) |
|---|---|
| Metoprolol Succinate | 0.88 |
| Placebo | -0.59 |
6MWD change from baseline to visit day 336. The 6MWD has been used as a simple tool to assess overall exercise tolerance in patients with chronic cardiopulmonary disease including COPD. (NCT02587351)
Timeframe: Baseline, 1 year
| Intervention | meters (Mean) |
|---|---|
| Metoprolol Succinate | -17.64 |
| Placebo | -11.87 |
Change in FEV1 % Predicted from baseline to visit day 336 as assessed by spirometry (NCT02587351)
Timeframe: 1 year
| Intervention | percentage of predicted (Mean) |
|---|---|
| Metoprolol Succinate | -2.24 |
| Placebo | -1.46 |
Number of hospital days resulting from acute exacerbations of COPD reported as negative binomial estimates of mean hospital days per patient year. (NCT02587351)
Timeframe: 14 months
| Intervention | hospital days (Mean) |
|---|---|
| Metoprolol Succinate | 3.09 |
| Placebo | 0.96 |
Modified Medical Research Council Dyspnea Scale (MMRC) change from baseline to visit day 336. The MMRC scale is a five-point scale originally published in 1959 that considers certain activities, such as walking or climbing stairs, which provoke breathlessness. Scale from 0 to 4 with lower scores indicating less breathlessness. (NCT02587351)
Timeframe: 1 year
| Intervention | score on a scale (Median) |
|---|---|
| Metoprolol Succinate | 2.0 |
| Placebo | 2.0 |
Number of acute exacerbations of COPD - rate per person-year (NCT02587351)
Timeframe: 1 year
| Intervention | no. of events/person-yr (Mean) |
|---|---|
| Metoprolol Succinate | 1.40 |
| Placebo | 1.33 |
Number of Emergency Department visits resulting from acute exacerbations of COPD - rate (NCT02587351)
Timeframe: 1 year
| Intervention | events per person-year (Mean) |
|---|---|
| Metoprolol Succinate | 0.17 |
| Placebo | 0.18 |
Number of hospital admissions resulting from acute exacerbations of COPD - rate (NCT02587351)
Timeframe: 1 year
| Intervention | events per person-year (Mean) |
|---|---|
| Metoprolol Succinate | 0.66 |
| Placebo | 0.42 |
"San Diego Shortness of Breath Questionnaire (SOBQ) change from baseline. A 24-item measure that assesses self-reported shortness of breath while performing a variety of activities of daily living. Each item has a 6-point scale (0 = not at all to 5 = maximal or unable to do because of breathlessness)." (NCT02587351)
Timeframe: 1 year
| Intervention | score on a scale (Mean) |
|---|---|
| Metoprolol Succinate | 0.52 |
| Placebo | -0.25 |
SGRQ change from baseline to visit day 336. The SGRQ total score change from baseline. SGRQ is a respiratory specific health status questionnaire with scores ranging from 0 to 100. The lower score indicates a better health status. (NCT02587351)
Timeframe: Baseline, 1 year
| Intervention | score on a scale (Mean) |
|---|---|
| Metoprolol Succinate | 0.52 |
| Placebo | -0.25 |
"Acute exacerbations are defined as a complex of respiratory symptoms (increase or new onset) of more than one of the following: cough, sputum, wheezing, dyspnea, or chest tightness requiring treatment with antibiotics and/or systemic steroids for at least three days." (NCT02587351)
Timeframe: 1 year
| Intervention | days (Mean) |
|---|---|
| Metoprolol Succinate | 202 |
| Placebo | 222 |
MACE defined by cardiovascular death, hospitalization for myocardial infarction, heart failure, or stroke (NCT02587351)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Myocardial Infarction | Heart Failure | Stroke | Sudden cardiac death | COPD Exacerbation (Serious) | |
| Metoprolol Succinate | 2 | 2 | 1 | 0 | 55 |
| Placebo | 1 | 3 | 1 | 1 | 32 |
New or worsened (Neural: depression, headache, syncope, seizures, somnolence, memory loss, loss of sexual desire or erectile dysfunction, and fatigue; Hypersensitivity: rash, pruritus, tongue or facial swelling; Gastrointestinal: diarrhea, vomiting, nausea or constipation; Cardiovascular: bradycardia and hypotension as discussed below; Respiratory: bronchospasm and changes in lung function as discussed below). (NCT02587351)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Depression | Headache | Fainting | Daytime Sleepiness | Memory Loss | Loss of sexual desire or erectile dysfunction | Lack of energy | Rash | Itching | Tongue or facial swelling | Vomiting | Nausea | Constipation | Wheezing | Shortness of breath | Chest tightness | Heart skipping or irregular beats | Dizziness/light headedness | |
| Metoprolol Succinate | 28 | 71 | 4 | 58 | 20 | 10 | 91 | 17 | 11 | 7 | 11 | 45 | 30 | 88 | 115 | 81 | 16 | 74 |
| Placebo | 39 | 78 | 8 | 70 | 21 | 6 | 77 | 21 | 18 | 5 | 18 | 42 | 32 | 79 | 112 | 80 | 15 | 64 |
Major adverse cardiovascular events (MACE), percutaneous coronary intervention or coronary artery bypass grafting. MACE defined by cardiovascular death, hospitalization for myocardial infarction, heart failure, or stroke (NCT02587351)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Myocardial Infarction | Heart Failure | Stroke | Sudden Cardiac Death | |
| Metoprolol Succinate | 2 | 2 | 1 | 0 |
| Placebo | 1 | 3 | 1 | 1 |
Fibrinogen: assessed at screening/randomization and at conclusion of the study to determine if beta-blockade impacts levels of systemic inflammation that portend overall cardiac risk. (NCT02587351)
Timeframe: Baseline, 1 year
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Fibrinogen baseline | Fibrinogen Visit 336 | |
| Metoprolol Succinate | 384.8 | 392.5 |
| Placebo | 378.2 | 386.0 |
Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The Bodily Pain Scale includes 2 items assessing the intensity of pain and effect of pain on normal work, both inside and outside the house. Items are transformed to a score with a range of 0-100. (NCT02587351)
Timeframe: 1 year
| Intervention | Units on a scale (Median) | ||
|---|---|---|---|
| Baseline | Day 112 visit | Day 336 Visit | |
| Metoprolol Succinate | 67.5 | 67.5 | 57.5 |
| Placebo | 67.5 | 67.5 | 57.5 |
Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The Emotional Well-being Scale includes 5 items assessing emotional wellbeing. Items are transformed to a score with a range of 0-100. (NCT02587351)
Timeframe: 1 year
| Intervention | Units on a scale (Median) | ||
|---|---|---|---|
| Baseline | Day 112 visit | Day 336 Visit | |
| Metoprolol Succinate | 76.0 | 76.0 | 76.0 |
| Placebo | 72.0 | 72.0 | 72.0 |
Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The Energy/Fatigue Scale includes 4 items. Items are transformed to a score with a range of 0-100. (NCT02587351)
Timeframe: 1 year
| Intervention | Units on a scale (Median) | ||
|---|---|---|---|
| Baseline | Day 112 visit | Day 336 Visit | |
| Metoprolol Succinate | 50.0 | 50.0 | 50.0 |
| Placebo | 50.0 | 45.0 | 45.0 |
Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The General Health Scale includes 4 items assessing personal evaluations of health. Items are transformed to a score with a range of 0-100. (NCT02587351)
Timeframe: 1 year
| Intervention | Units on a scale (Median) | ||
|---|---|---|---|
| Baseline | Day 112 visit | Day 336 Visit | |
| Metoprolol Succinate | 40.0 | 40.0 | 40.0 |
| Placebo | 40.0 | 35.0 | 35.0 |
Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. 8 multi-item scales with higher score indicating better health state. The Physical Functioning scale is 10 items assessing the extent to which health limits physical activities such as self-care, walking, climbing stairs, bending lifting, and moderate and vigorous activities transformed to a score with a range of 0-100. (NCT02587351)
Timeframe: 1 year
| Intervention | Units on a scale (Median) | ||
|---|---|---|---|
| Baseline | Day 112 visit | Day 336 Visit | |
| Metoprolol Succinate | 30.0 | 30.0 | 30.0 |
| Placebo | 30.0 | 30.0 | 35.0 |
Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The Role Functioning - Emotional Scale includes 3 items assessing extent to which emotional problems interfere with work or other daily activities. Items are transformed to a score with a range of 0-100. (NCT02587351)
Timeframe: 1 year
| Intervention | Units on a scale (Median) | ||
|---|---|---|---|
| Baseline | Day 112 visit | Day 336 Visit | |
| Metoprolol Succinate | 100.0 | 66.7 | 66.7 |
| Placebo | 66.7 | 66.7 | 66.7 |
Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The Role Functioning - Physical Scale contains 4 items assessing the extent to which physical health interferes with work or other daily activities, including accomplished less than wanted, limitations in the kind of activities. Items are transformed to a score with a range of 0-100. (NCT02587351)
Timeframe: 1 year
| Intervention | Units on a scale (Median) | ||
|---|---|---|---|
| Baseline | Day 112 visit | Day 336 Visit | |
| Metoprolol Succinate | 25.0 | 25.0 | 12.5 |
| Placebo | 25.0 | 25.0 | 12.5 |
Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The Social Functioning Scale includes 2 items assessing extent to which physical health or emotional problems interfere with normal social activities. Items are transformed to a score with a range of 0-100. (NCT02587351)
Timeframe: 1 year
| Intervention | Units on a scale (Median) | ||
|---|---|---|---|
| Baseline | Day 112 visit | Day 336 Visit | |
| Metoprolol Succinate | 62.5 | 62.5 | 75.0 |
| Placebo | 62.5 | 62.5 | 62.5 |
2 reviews available for metoprolol and Disease Exacerbation
| Article | Year |
|---|---|
Metoprolol: a review of its use in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Chemistry, Pharmaceutical; Disease Progression; Heart Failure; Hemodyna | 2000 |
[Role of beta-blockers in the treatment of chronic heart heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Controlled Clinica | 2001 |
11 trials available for metoprolol and Disease Exacerbation
| Article | Year |
|---|---|
Association between P-pulmonale and respiratory morbidity in COPD: a secondary analysis of the BLOCK-COPD trial.
Topics: Adrenergic beta-Antagonists; Disease Progression; Humans; Metoprolol; Morbidity; Pulmonary Disease, | 2023 |
Metoprolol for the Prevention of Acute Exacerbations of COPD.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Disease Progression; Female; Forced | 2019 |
Effects of additional vasodilatory or nonvasodilatory treatment on renal function, vascular resistance and oxygenation in chronic kidney disease: a randomized clinical trial.
Topics: Amlodipine; Angiotensins; Antihypertensive Agents; Disease Progression; Glomerular Filtration Rate; | 2019 |
β-Blockers for the prevention of acute exacerbations of chronic obstructive pulmonary disease (βLOCK COPD): a randomised controlled study protocol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Cause of Death; Disease Progression; Do | 2016 |
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
Coordinate changes in Myosin heavy chain isoform gene expression are selectively associated with alterations in dilated cardiomyopathy phenotype.
Topics: Antihypertensive Agents; Atrial Natriuretic Factor; Biopsy; Calcium-Transporting ATPases; Carbazoles | 2002 |
The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blac | 2005 |
Symptoms in patients with heart failure are prognostic predictors: insights from COMET.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Carbazoles; Carvedilol; Disease Progression; Dou | 2005 |
The effect of weight loss intervention on antihypertensive medication requirements in the hypertension Optimal Treatment (HOT) study.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bloo | 1999 |
Acute precipitants of congestive heart failure exacerbations.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Dise | 2001 |
Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carotid Artery Diseases; Cholesterol, LDL; Delayed-Acti | 2002 |
16 other studies available for metoprolol and Disease Exacerbation
| Article | Year |
|---|---|
Beta-blocker Use in Moderate and Severe Chronic Obstructive Pulmonary Disease.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bisoprolol; Case-Control | 2019 |
Metoprolol blunts the time-dependent progression of infarct size.
Topics: Administration, Intravenous; Adrenergic beta-1 Receptor Antagonists; Animals; Cardiac Imaging Techni | 2020 |
Beta-Adrenergic Antagonists and Cancer Specific Survival in Patients With Advanced Prostate Cancer: A Veterans Administration Cohort Study.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Androgen Antagonists; Bone Neoplasm | 2021 |
The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Chi-Square | 2017 |
Update on pharmacological advances.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Disea | 2004 |
MicroRNA-133 modulates the β1-adrenergic receptor transduction cascade.
Topics: 3' Untranslated Regions; Adenylyl Cyclases; Animals; Apoptosis; Cells, Cultured; Cyclic AMP; Cyclic | 2014 |
"Qufeng Tongluo" acupuncture prevents the progression of glomerulonephritis by decreasing renal sympathetic nerve activity.
Topics: Acupuncture Therapy; Animals; Biphenyl Compounds; Disease Models, Animal; Disease Progression; Glome | 2014 |
Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Disease Progression; Female; Genotype; Ha | 2008 |
Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardio | 2008 |
Atrial fibrillation degenerates into ventricular fibrillation.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Defibrillators, Impla | 2010 |
[Efficacy of ivabradine in combination therapy for complicated acute coronary syndrome in patients with type 2 diabetes mellitus].
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Adult; Benzazepines; Diabetes Mellitus, Type 2 | 2010 |
Which beta-blocker is most effective in heart failure?
Topics: Adrenergic beta-Antagonists; Animals; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Clinical Tria | 2010 |
Computed tomography angiography for right ventricular function in an adult with complex congenital heart disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Calcium Channel Blockers; Coronary Angiography; Diltiazem; D | 2010 |
Heart failure: acute ischemic events in HF--should we include sudden death?
Topics: Adrenergic beta-1 Receptor Antagonists; Antihypertensive Agents; Benzopyrans; Death, Sudden, Cardiac | 2011 |
Heart rate-associated mechanical stress impairs carotid but not cerebral artery compliance in dyslipidemic atherosclerotic mice.
Topics: Animals; Anti-Arrhythmia Agents; Apolipoproteins B; Atherosclerosis; Benzazepines; Carotid Arteries; | 2011 |
Chronic kidney disease--a disease domain complex.
Topics: Aged; Alendronate; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Asp | 2008 |